echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Wuxi drug import port was approved to expand the opening platform channel

    Wuxi drug import port was approved to expand the opening platform channel

    • Last Update: 2020-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, Wuxi biopharmaceutical industry has developed strongly, with 792 biopharmaceutical enterprises in Wuxi in 2019, up 12.8% YoY, and achieving output value of more than 80 billion yuan, up 17% YoY.
    of Wuxi's top 100 tax-paying enterprises, 6 are biopharmaceutical enterprises, and the city owns 7 listed enterprises such as Pharmaceutical Mingkang, Xiangsheng Medical.
    In March this year, Wuxi launched "Several Measures to Accelerate the Development of the Modern Biopharmaceutical Industry in Wuxi City" (hereinafter referred to as "Measures"), with a total of 15 measures, referring to the need to focus on five areas, such as innovative drugs, high-end medical devices and high-quality generic drug research and development, major innovation centers and the construction of key enterprise technology public service platforms.
    the support of the new policy, there is no doubt that the development of pharmaceutical companies to play a strong heart.
    September 14th, Wuxi welcomed the good news that drug import ports had been approved.
    this is also the first city in China to be approved for air and water ports since the implementation of the drug import port declaration policy in 2015.
    After the drug import port is approved, the local people no longer need to bypass the foreign or overseas to buy imported drugs, but also to help pharmaceutical companies reduce the cost and efficiency to open up the drug entry channel, and expand the opening platform channel, for the new introduction of biopharmaceutical projects to provide strong support.
    As a city with a concentration of foreign-funded pharmaceutical enterprises, Wuxi pharmaceutical industry as a whole presents a good trend of initial cluster-type and deepening development, and pharmaceutical research and development outsourcing CRO enterprises, new drug research and development enterprises and generic drug research and development enterprises are the key directions attracted by the city.
    , Wuxi is home to more than 40 well-documented pharmaceutical manufacturers, including foreign companies such as AstraZeneta and Pfizer, as well as local pharmaceutical companies such as Drug Mingkang.
    these companies generally have a demand for small quantities of imported drugs.
    , for example, pharmaceutical Mingkang, as a research and development outsourcing CRO enterprises, in the process of providing some foreign customers with new drug research and development services, the need to import a lot of drugs in small quantities.
    It is understood that, according to China's Measures for the Administration of Drug Registration and the Measures for the Administration of Drug Imports, pharmaceutical research and development institutions or pharmaceutical production enterprises may apply for one-time imports of drugs that have been listed outside China but are not listed in China for the purpose of drug registration in China, and for research aimed at the consistent evaluation of the quality and efficacy of generic drugs.
    , the opening of The Wuxi Drug Import Port will further facilitate the development of pharmaceutical companies, attracting more of this type of enterprises to the city.
    small batch imports do not need to declare too many materials and procedures, drug research and development time and costs will be reduced, good for the development of enterprises.
    it is learned that after the drug import port was approved, Wuxi City Market Supervision Bureau has led a multi-sectoral joint formulation of "Wuxi City on the promotion of drug import port business development of a number of measures" (hereinafter referred to as "Measures").
    the Measures, there are seven articles and ten articles.
    This includes the construction of port drug regulatory departments, port drug inspection institutes, customs, import units and other "four-in-one" exchange platform, as well as "detailed customs clearance services" "providing commissioned inspection business" "developing the introduction of air and water transport subsidy policy" "rent relief policy" "providing digital financial services" and other content, will further expand the access of foreign biopharmaceutical products into the Chinese market, promote the development of Wuxi biopharmaceutical industry.
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.